Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept

Autor:	Jeffrey M Weinberg, William D Tutrone
Rok vydání:	2006
Předmět:	musculoskeletal diseases medicine.medical_specialty business.industry Efalizumab Dermatology Disease medicine.disease Alefacept Infliximab Etanercept Psoriasis medicine Adalimumab Tumor necrosis factor alpha business medicine.drug
Zdroj:	Expert Review of Dermatology. 1:207-216
ISSN:	1746-9880 1746-9872
DOI:	10.1586/17469872.1.2.207
Popis:	Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European populations. Over the last few years, one of the major focuses in psoriasis research has been the development of biological therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to update the progress of the tumor necrosis factor inhibitors that are available, or under investigation, for clinical use in psoriasis: infliximab, etanercept and adalimumab, as well as the T-cell-targeted therapies efalizumab and alefacept.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::360db8b952f55d1223a0397d2b2b2a81 https://doi.org/10.1586/17469872.1.2.207 Zobrazit plný text záznamu